Collagen Peptides (Hydrolysed Collagen), Research Reference
Collagen peptides, also known as hydrolysed collagen or collagen hydrolysate, are short amino acid sequences produced by enzymatic hydrolysis of full-length collagen proteins. Unlike intact collagen, which is poorly absorbed in the gastrointestinal tract, collagen peptides are cleaved to dipeptides and tripeptides that are absorbed intact and detectable in plasma and target tissues. Collagen is the most abundant structural protein in the human body, comprising approximately 30% of total protein mass, and forms the primary scaffold of skin, bone, cartilage, tendon, ligament, and gut tissue. Research has investigated oral collagen peptide supplementation for skin elasticity, joint health, bone density, muscle recovery, and gut barrier function across multiple randomised controlled trials.
Quick Reference
| Also known as | Hydrolysed collagen, collagen hydrolysate, collagen peptide supplement |
| Source | Bovine (most common), marine (fish), porcine, or avian; primarily type I and III collagen |
| Molecular weight | Typically 2,000 to 5,000 Da (hydrolysed fragments; varies by manufacturer) |
| Administration | Oral (powder dissolved in liquid, capsule, or liquid); not injectable |
| Common dose range | 2.5 g to 15 g per day depending on indication; most trials use 5 g to 10 g |
| Key bioactive fragments | Pro-Hyp (proline-hydroxyproline), Gly-Pro-Hyp (glycine-proline-hydroxyproline) |
| Primary research areas | Skin elasticity and hydration, joint cartilage, bone mineral density, tendon repair, muscle recovery, gut barrier |
| Vitamin C co-administration | Consistently recommended in research protocols; ascorbate is a required cofactor for proline and lysine hydroxylation during collagen biosynthesis |
| Regulatory status | Classified as food supplement or dietary supplement in most jurisdictions; not a drug; not subject to pharmaceutical approval |
| Research classification | Active human clinical trial data across multiple randomised controlled trials; meta-analyses published for skin and joint endpoints |
What Are Collagen Peptides?
Collagen is a family of structural proteins characterised by a triple-helix arrangement of three polypeptide chains rich in glycine, proline, and hydroxyproline. The human body contains at least 28 distinct collagen types, of which types I, II, and III account for the vast majority of total collagen mass. Type I collagen is the predominant form in skin, bone, tendon, ligament, and cornea. Type II collagen is the primary collagen of hyaline cartilage. Type III collagen is found alongside type I in skin and blood vessel walls and is particularly associated with wound healing and tissue repair.
Collagen peptides are produced by controlled enzymatic hydrolysis of native collagen, typically from bovine hides, fish skin and scales, or porcine sources. Hydrolysis cleaves the intact triple-helix structure at specific peptide bonds, generating fragments with average molecular weights of 2,000 to 5,000 daltons, compared to the approximately 300,000 dalton molecular weight of full-length type I collagen. This size reduction is pharmacokinetically significant: intact collagen molecules are too large for meaningful intestinal absorption, while collagen peptide fragments, particularly the dipeptide Pro-Hyp and tripeptide Gly-Pro-Hyp, are absorbed intact across the intestinal epithelium and detectable in plasma within 1 to 2 hours of oral administration.
The distinction between collagen peptides and gelatin is relevant: gelatin is partially denatured collagen produced by heat treatment, which breaks the triple helix but does not fully hydrolyse the peptide bonds. Gelatin forms gels and is not water-soluble at room temperature. Collagen peptides are fully hydrolysed, water-soluble at room temperature, and have the specific low-molecular-weight profile associated with oral bioavailability in research models.
Mechanism of Action
Intestinal Absorption and Bioavailability
Following oral ingestion, collagen peptides are digested by gastrointestinal proteases to small fragments. Unlike most dietary proteins, which are fully broken down to free amino acids, a proportion of collagen peptides resist complete hydrolysis due to the unusual abundance of the imino acid proline, which is not efficiently recognised by many common peptidases. As a result, the dipeptide Pro-Hyp and tripeptide Gly-Pro-Hyp reach the intestinal epithelium as intact peptides and are absorbed via di/tripeptide transporter pathways, notably PepT1. Plasma pharmacokinetic studies have confirmed peak Pro-Hyp concentrations within 1 hour of oral collagen peptide ingestion, with subsequent distribution to skin, cartilage, and periarticular tissue.
Fibroblast Stimulation and Collagen Synthesis
Research has proposed that bioactive collagen peptides, particularly Pro-Hyp and Gly-Pro-Hyp, act as signalling fragments that stimulate fibroblasts and chondrocytes to produce endogenous collagen. In vitro studies have demonstrated that Pro-Hyp increases fibroblast proliferation, migration, and collagen synthesis. The proposed mechanism involves binding to specific cell surface receptors or intracellular sensors that interpret the presence of collagen fragment sequences as a signal to upregulate matrix synthesis, analogous to a homeostatic feedback loop responding to collagen degradation products. This mechanism is distinct from the gene-expression-level signalling of copper peptides like GHK-Cu and AHK-Cu, which operate through receptor-mediated transcriptional activation.
Chondrocyte and Cartilage Matrix Support
In articular cartilage research, collagen peptides have been investigated for their potential to stimulate chondrocyte synthesis of both collagen type II and aggrecan, the primary proteoglycan of the cartilage extracellular matrix. Chondrocytes in culture exposed to Pro-Hyp and Gly-Pro-Hyp fragments demonstrate increased synthesis of type II collagen and glycosaminoglycans in vitro. This is proposed to support cartilage extracellular matrix integrity and may explain improvements in joint pain and function observed in randomised trials. Human pharmacokinetic studies have confirmed that collagen peptide fragments accumulate in joint cartilage following oral supplementation.
Osteoblast Activity and Bone Mineralisation
Research has investigated the effects of specific bioactive collagen peptides on osteoblast activity in bone tissue. In vitro evidence suggests that collagen fragments stimulate osteoblast differentiation and matrix synthesis, while simultaneously reducing markers of osteoclast activity. Clinical trials in postmenopausal women have reported increases in bone formation markers, including bone-specific alkaline phosphatase and P1NP (procollagen type 1 N-terminal propeptide), following specific bioactive collagen peptide supplementation, consistent with enhanced bone matrix production rather than simply anti-resorptive effects.
Amino Acid Substrate Provision
Beyond signalling mechanisms, collagen peptides provide concentrated glycine, proline, and hydroxyproline, amino acids that are rate-limiting for collagen biosynthesis. Glycine alone constitutes approximately one-third of all amino acids in collagen by position. The biosynthetic pathway for hydroxylation of proline to hydroxyproline requires both oxygen and ascorbic acid (vitamin C) as cofactors for prolyl hydroxylase, which is why vitamin C co-administration is consistently included in collagen peptide research protocols: without adequate ascorbate, the hydroxylation step required for triple-helix stability is impaired, and newly synthesised procollagen is degraded before secretion.
Research Evidence
Skin Elasticity, Hydration, and Wrinkle Reduction
Skin is among the most extensively researched targets for collagen peptide supplementation, with multiple randomised controlled trials and systematic reviews published. A 2019 systematic review and meta-analysis published in the Journal of Drugs in Dermatology analysed 11 placebo-controlled studies and concluded that oral collagen peptide supplementation produced statistically significant improvements in skin elasticity, hydration, and the appearance of wrinkles compared to placebo. Studies have used varied assessment methods including cutometer measurements of skin elasticity, corneometry for hydration, and standardised photography for wrinkle quantification. Effective dose ranges across trials span 2.5 g to 10 g per day, with study durations of 8 to 12 weeks representing the most common protocol length. Dermal collagen density has been assessed histologically in some trials, with reported increases in collagen fibril density in the papillary dermis following supplementation.
Joint Health and Osteoarthritis
Collagen peptides have been investigated for joint health outcomes in both clinical and preclinical models. A randomised controlled trial published in Current Medical Research and Opinion found that specific collagen hydrolysate supplementation significantly reduced joint pain in athletes with activity-related joint discomfort compared to placebo over 24 weeks. Multiple randomised trials in patients with osteoarthritis have used WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scoring to assess outcomes, with several reporting improvements in pain and functional subscales. A 2021 meta-analysis of collagen supplementation studies in osteoarthritis reported statistically significant improvements in pain scores across pooled trials. The cartilage-specific mechanism, accumulation of Pro-Hyp and Gly-Pro-Hyp in periarticular tissue and stimulation of chondrocyte matrix synthesis, provides a biological rationale for these observations.
Bone Mineral Density in Postmenopausal Women
Bone density research has specifically investigated specific bioactive collagen peptides (FORTIBONE, a branded preparation from GELITA) in postmenopausal women. A randomised controlled trial published in Nutrients (2018) investigated supplementation over 12 months and reported significant increases in bone mineral density at the lumbar spine and femoral neck compared to placebo. The same group published follow-on data reporting increases in bone formation markers alongside reductions in bone resorption markers, suggesting that the effect was driven by net positive bone remodelling rather than anti-resorption alone. This research is directly relevant to the accelerated bone loss that accompanies estrogen decline in the postmenopausal period.
Tendon and Connective Tissue Repair
Research by Shaw et al. published in the American Journal of Clinical Nutrition investigated the effect of vitamin C-enriched collagen peptide supplementation on collagen synthesis markers in the context of simulated exercise. A randomised crossover design showed that ingestion of 15 g of gelatin with 48 mg of vitamin C one hour before a jump-rope protocol significantly increased circulating markers of collagen synthesis compared to placebo. This suggested that collagen peptide ingestion timed before exercise could enhance connective tissue synthesis during the post-exercise repair window. Subsequent research has extended these findings to collagen hydrolysate specifically, with protocols typically recommending 5 g to 10 g collagen peptides plus 50 mg vitamin C administered 30 to 60 minutes before exercise.
Gut Barrier and Intestinal Health
Collagen peptides have been investigated for their potential role in supporting gut mucosal integrity. The intestinal epithelium is itself a collagen-rich structure, and the lamina propria beneath the epithelium contains abundant type I and III collagen. Research has investigated whether collagen peptide supplementation can support gut barrier function by providing substrate for mucosal collagen synthesis and by the direct effects of glycine on gut immune cells. Glycine has been shown to reduce pro-inflammatory cytokine production in macrophages and gut-associated immune cells through its action on glycine-gated chloride channels. Human trial data in this area is more limited than for skin and joint endpoints, but the gut-targeted research application of collagen peptides is mechanistically supported.
Muscle Recovery and Body Composition
Research has investigated collagen peptides in the context of exercise recovery and body composition, primarily in older adults and clinical populations. A randomised trial in sarcopenic elderly men found that collagen peptide supplementation combined with resistance training produced significantly greater improvements in fat-free mass and muscle strength compared to exercise plus placebo. The proposed mechanism is not direct stimulation of myoprotein synthesis (collagen is not a complete protein and lacks tryptophan) but rather support of the connective tissue scaffold surrounding and transmitting force from skeletal muscle, including tendons, fasciae, and periosteum. Post-exercise collagen synthesis protocols are increasingly referenced in sports nutrition research as a distinct application from myoprotein synthesis strategies based on whey or leucine-rich proteins.
Collagen Types: Research Context
| Type | Primary Location | Research Application | Common Source |
|---|---|---|---|
| Type I | Skin, bone, tendon, ligament, cornea | Skin elasticity, bone density, tendon repair | Bovine hide, fish, porcine |
| Type II | Articular cartilage, vitreous humour | Joint health, osteoarthritis, cartilage repair | Chicken sternum, bovine cartilage |
| Type III | Skin, blood vessel walls, intestine | Skin repair, wound healing, gut mucosal health | Bovine hide, porcine, marine |
| Type IV | Basement membranes | Vascular and renal research; not common in supplements | Not typically in commercial supplements |
| Type V | Bone, skin, cornea (co-localised with type I) | Bone and corneal research contexts | Present at low levels in bovine sources |
Most commercial and research-grade collagen peptide preparations are derived from type I and III collagen sources, primarily bovine hide or marine (fish) collagen. The bioactive dipeptides and tripeptides generated by hydrolysis of type I and III collagen (Pro-Hyp, Gly-Pro-Hyp) are the same regardless of source, making bovine and marine collagen peptides pharmacokinetically similar in terms of bioavailable fragment profile. Marine collagen peptides have a lower average molecular weight than bovine, which some researchers propose increases intestinal absorption, though direct comparative trial data are limited.
Reported Protocols
The following protocol information is derived from published clinical trial designs and anecdotal research reports. It is educational reference only. Collagen peptides are oral supplements, not pharmaceuticals, and are not subject to prescription requirements in most jurisdictions.
Skin Elasticity Protocol
Dose: 2.5 g to 10 g collagen peptides per day, taken with 50 to 100 mg vitamin C. Duration: minimum 8 weeks, with most trials using 8 to 12 weeks for detectable skin parameter changes. Timing: once daily, typically with a meal. Source type: type I bovine or marine collagen peptides are most commonly used in skin research. Most published trials specify a molecular weight of 2,000 to 3,000 Da for the peptide preparation used.
Joint Health Protocol
Dose: 5 g to 10 g collagen peptides per day, with 50 mg vitamin C. Duration: 12 to 24 weeks for joint and cartilage outcomes. Timing: once daily. Source type: clinical trials in joint health have used both type I bovine and specific branded collagen hydrolysate preparations. Some joint research protocols specify type II chicken collagen (undenatured collagen type II, UC-II) at lower doses (40 mg), which operates through a different proposed mechanism, oral tolerance, rather than the substrate-and-signalling mechanism of hydrolysed collagen peptides.
Bone Density Protocol
Dose: 5 g specific bioactive collagen peptides per day. Duration: 12 months minimum in clinical trials investigating bone mineral density. Target population in published trials: postmenopausal women. Outcomes measured: dual-energy X-ray absorptiometry (DXA) for bone mineral density at lumbar spine and femoral neck, alongside bone formation (P1NP, bone ALP) and bone resorption (CTX) markers.
Connective Tissue and Exercise Protocol
Dose: 5 g to 15 g hydrolysed collagen or gelatin with 50 mg vitamin C. Timing: 30 to 60 minutes before exercise or specific connective tissue loading. Rationale: research has demonstrated that plasma amino acid levels, including proline and hydroxyproline, peak approximately 60 minutes after collagen peptide ingestion, coinciding with the exercise-induced increase in connective tissue remodelling. Administration before exercise may therefore support collagen synthesis during the post-exercise repair window.
Collagen Peptides vs GHK-Cu / AHK-Cu
| Feature | Collagen Peptides | GHK-Cu | AHK-Cu |
|---|---|---|---|
| Structure | Mixed dipeptides and tripeptides (Pro-Hyp, Gly-Pro-Hyp); 2,000 to 5,000 Da average | Tripeptide Gly-His-Lys bound to copper; 340 Da | Tripeptide Ala-His-Lys bound to copper; 354 Da |
| Mechanism | Substrate provision; fibroblast and chondrocyte stimulation via bioactive fragment signalling | Receptor-mediated gene expression upregulation; copper delivery for enzymatic cofactors | Dermal papilla receptor signalling; VEGF upregulation; anti-apoptotic effects on follicle cells |
| Administration | Oral (powder, capsule, liquid); no injection required | Topical (cosmetic) or subcutaneous injection (research) | Topical (scalp serums); subcutaneous in some research protocols |
| Clinical evidence | Multiple randomised controlled trials; meta-analyses published for skin and joint endpoints | Strong preclinical literature; limited human RCT data for injectable routes | Preclinical (ex vivo hair follicle data); limited human RCT data |
| Primary skin target | Fibroblasts; dermal collagen structural proteins | Broad skin biology; fibroblasts, keratinocytes; antioxidant gene networks | Dermal papilla cells; hair follicle vasculature |
| Regulatory classification | Dietary/food supplement in most jurisdictions; widely available | Cosmetic ingredient (topical); research compound (injectable); not approved for any indication | Cosmetic ingredient (topical; INCI: Copper Tripeptide-3); not approved for any indication |
Safety & Tolerability
| Consideration | Detail |
|---|---|
| General tolerability | Collagen peptides are consistently well-tolerated in clinical trials, with adverse event rates generally comparable to placebo across randomised studies. No serious adverse events attributable to collagen peptide supplementation have been reported in published trials. |
| Common reported effects | Mild gastrointestinal symptoms (bloating, fullness) reported in a minority of users, typically at doses above 10 g; generally transient and self-resolving. |
| Allergen considerations | Bovine-derived collagen peptides are contraindicated in individuals with beef protein allergy. Marine-derived collagen peptides are contraindicated in fish or shellfish allergies depending on source species. Kosher and halal certifications vary by manufacturer. |
| Kidney considerations | Collagen peptides contribute to amino acid load; individuals with renal insufficiency should consult a clinician before high-dose supplementation, as with any concentrated protein source. |
| Heavy metal risk | Third-party testing for heavy metals, particularly lead, is important when selecting collagen peptide products, as bone-sourced collagen preparations can contain residual lead. Skin and hide-sourced collagen peptides generally have lower heavy metal content than bone-meal-derived products. |
| Drug interactions | No significant drug interactions documented. Vitamin C co-supplementation at common research doses (50 to 200 mg per day) is safe for most individuals; high-dose vitamin C may interact with certain medications in clinical contexts. |
| Pregnancy and lactation | No specific safety data for collagen peptide supplementation in pregnancy. Consultation with a clinician is recommended before use during pregnancy or breastfeeding. |
Regulatory Status
Collagen peptides are classified as dietary supplements in the United States under the Dietary Supplement Health and Education Act (DSHEA) and as food supplements under European Union Regulation No 178/2002. They are not subject to the pharmaceutical drug approval process in any major jurisdiction, meaning they do not require demonstration of clinical efficacy or safety to the standard required for approved medicines before being placed on the market.
This regulatory classification has practical implications for researchers. Collagen peptide products vary widely in quality, molecular weight distribution, source species, and degree of hydrolysis. The specific peptide preparations studied in randomised clinical trials are not necessarily interchangeable with generic collagen peptide powders of unknown characterisation. Research conclusions from trials using specific branded preparations may not generalise to all collagen peptide products. Additionally, no collagen peptide product may be marketed with disease treatment claims in most jurisdictions; permitted claims are structure/function claims (e.g., supports healthy joints) rather than therapeutic claims.
GRAS (Generally Recognised As Safe) status has been granted to collagen peptide preparations by the US FDA for use as food ingredients, reflecting their established safety profile as food-derived compounds. No collagen peptide is approved as a drug for the treatment of any condition. This contrasts with the research compound status of GHK-Cu and AHK-Cu, which lack the dietary supplement classification and broader regulatory framework applicable to food-derived peptide preparations.
Related Pages
Related Peptides: GHK-Cu (Copper Tripeptide-1) · AHK-Cu (Copper Tripeptide-3) · BPC-157
Goals: Skin, Hair & Cosmetic · Recovery & Healing · Muscle Growth & Body Composition · Inflammation & Anti-inflammatory Research · Gut Health & GI Support · Menopause & Perimenopause